Merck considering takeover of Cubist Pharmaceuticals

posted by Phill Allen

December, 08th, 2014

Company News

American drug giant Merck is reportedly eying up a possible acquisition of the biopharmaceuticals company Cubist Pharmaceuticals.
Merck considering takeover of Cubist Pharmaceuticals
The deal, according to the New York Times, could be announced as early as next week. Merck could pay around $100 a share in a move which would value the US antibiotics maker in the range of $7.5 billion.
Cubist, which makes drugs to treat dangerous bacteria and superbugs in the developing world, has seen its share value nearly double over the last two years.
Should the deal go through it would mark the latest in a long line of multibillion-dollar pharmaceutical mergers and acquisitions.
Merck, one of America’s largest makers of vaccines, prescription products and oncology treatments, has a market value in excess of $174 billion.

Related reading:

TAGS: Cubist Pharmaceuticals, Merck, Pharmaceutical company,



Phill Allen

Managing Director

An in and outside the (bioprocess) box thinker, fluid management specialist Phill knows a thing or two about keeping pharma liquid logistics flowing.

ALLpaQ’s Net Zero Goal
Company News Pharmaceutical Industry News

ALLpaQ’s Net Zero Goal

No business can ignore their Carbon Footprint, nor their responsibilities to achieve Net Zero carbon emissions. At ALLpaQ, we believe […]

Oct 05th, 2022